Cargando…

Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications

Gut microbiota dysregulation plays a key role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) through its metabolites. Therefore, the restoration of the gut microbiota and supplementation with commensal bacterial metabolites can be of therapeutic benefit against the disease. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jiezhong, Vitetta, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432372/
https://www.ncbi.nlm.nih.gov/pubmed/32717871
http://dx.doi.org/10.3390/ijms21155214
_version_ 1783571783071301632
author Chen, Jiezhong
Vitetta, Luis
author_facet Chen, Jiezhong
Vitetta, Luis
author_sort Chen, Jiezhong
collection PubMed
description Gut microbiota dysregulation plays a key role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) through its metabolites. Therefore, the restoration of the gut microbiota and supplementation with commensal bacterial metabolites can be of therapeutic benefit against the disease. In this review, we summarize the roles of various bacterial metabolites in the pathogenesis of NAFLD and their therapeutic implications. The gut microbiota dysregulation is a feature of NAFLD, and the signatures of gut microbiota are associated with the severity of the disease through altered bacterial metabolites. Disturbance of bile acid metabolism leads to underactivation of bile acid receptors FXR and TGR5, causal for decreased energy expenditure, increased lipogenesis, increased bile acid synthesis and increased macrophage activity. Decreased production of butyrate results in increased intestinal inflammation, increased gut permeability, endotoxemia and systemic inflammation. Dysregulation of amino acids and choline also contributes to lipid accumulation and to a chronic inflammatory status. In some NAFLD patients, overproduction of ethanol produced by bacteria is responsible for hepatic inflammation. Many approaches including probiotics, prebiotics, synbiotics, faecal microbiome transplantation and a fasting-mimicking diet have been applied to restore the gut microbiota for the improvement of NAFLD.
format Online
Article
Text
id pubmed-7432372
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74323722020-08-24 Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications Chen, Jiezhong Vitetta, Luis Int J Mol Sci Review Gut microbiota dysregulation plays a key role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) through its metabolites. Therefore, the restoration of the gut microbiota and supplementation with commensal bacterial metabolites can be of therapeutic benefit against the disease. In this review, we summarize the roles of various bacterial metabolites in the pathogenesis of NAFLD and their therapeutic implications. The gut microbiota dysregulation is a feature of NAFLD, and the signatures of gut microbiota are associated with the severity of the disease through altered bacterial metabolites. Disturbance of bile acid metabolism leads to underactivation of bile acid receptors FXR and TGR5, causal for decreased energy expenditure, increased lipogenesis, increased bile acid synthesis and increased macrophage activity. Decreased production of butyrate results in increased intestinal inflammation, increased gut permeability, endotoxemia and systemic inflammation. Dysregulation of amino acids and choline also contributes to lipid accumulation and to a chronic inflammatory status. In some NAFLD patients, overproduction of ethanol produced by bacteria is responsible for hepatic inflammation. Many approaches including probiotics, prebiotics, synbiotics, faecal microbiome transplantation and a fasting-mimicking diet have been applied to restore the gut microbiota for the improvement of NAFLD. MDPI 2020-07-23 /pmc/articles/PMC7432372/ /pubmed/32717871 http://dx.doi.org/10.3390/ijms21155214 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chen, Jiezhong
Vitetta, Luis
Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications
title Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications
title_full Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications
title_fullStr Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications
title_full_unstemmed Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications
title_short Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications
title_sort gut microbiota metabolites in nafld pathogenesis and therapeutic implications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432372/
https://www.ncbi.nlm.nih.gov/pubmed/32717871
http://dx.doi.org/10.3390/ijms21155214
work_keys_str_mv AT chenjiezhong gutmicrobiotametabolitesinnafldpathogenesisandtherapeuticimplications
AT vitettaluis gutmicrobiotametabolitesinnafldpathogenesisandtherapeuticimplications